Not provided
Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| 54179060CLL4033 | Other Identifier | Janssen Research & Development, LLC |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of this study is to assess the impact of an individual physical activity intervention (IPAI) on health-related quality of life (HRQoL) in participants with first line or relapsed chronic lymphocytic leukemia (CLL) initiating ibrutinib in a routine clinical practice setting. HRQoL will be measured using functional assessment of cancer therapy - general scale (FACT-G).
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Group 1: Individual Physical Activity Intervention | Participants with chronic lymphocytic leukemia (CLL) will be invited to perform physical activity according to a predefined intervention program. This program includes walking and weekly remote adapted physical activity sessions (2 sessions per week, the duration and difficulty of which will be adapted by the adapted physical activity [APA] trainer according to the Participant's abilities). |
| |
| Group 2: Standard of Care | Participants with CLL will continue physical activity according to their lifestyle and the recommendations of the medical team. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Individual Physical Activity Intervention (IPAI) | Behavioral | No drug will be administered as a part of this study. The intervention will consist in an IPAI provided to participants for 6 months to practice physical activity in addition to their medical treatment in routine clinical practice settings. IPAI will be an adaptive program and will comprise two periods, the first period consisting in a supervised 4-month program and the second one in an unsupervised 2-month program to achieve greater autonomy. |
| Measure | Description | Time Frame |
|---|---|---|
| Change from Baseline in Health-related Quality of Life (HRQoL) by Using Functional Assessment of Cancer Therapy General (FACT-G) Total Score at Month 4.5 | The FACT-G consists of 27 questions grouped in 4 dimensions: physical well-being (PWB; 7 items), social/family well-being (SWB; 7 items), emotional well-being (EWB; 6 items), and functional well-being (FWB; 7 items). Each item is given a weighted score of 0 to 4 and the score of each dimension are obtained by addition of the weighted scores of each item corresponding to the dimension. Total FACT-G score is the summation of 4 subscale scores and ranges from 0-108. Higher scores for the scales and subscales indicate better HRQoL. | Baseline and Month 4.5 |
| Measure | Description | Time Frame |
|---|---|---|
| Change from Baseline in HRQoL by Using Functional Assessment of Cancer Therapy - Leukemia (FACT-Leu) Total Score at Month 4.5, Month 6.5 and Month 12 | The FACT-Leu questionnaire consists of 44 questions grouped into 5 dimensions: PWB (7 items), SWB (7 items), EWB (6 items), FWB (7 items) and additional concerns (LEUS; 17 items). Each item is given a weighted score of 0 to 4 and the score of each dimension are obtained by addition of the weighted scores of each item corresponding to the dimension. Total FACT-Leu score is the summation of 5 subscale scores and ranges from 0-176. Higher scores for the scales and subscales indicate better HRQoL. |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
The study population will include participants aged at least 18 years of age with chronic lymphocytic leukemia (CLL).
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Study Contact | Contact | 844-434-4210 | Participate-In-This-Study1@its.jnj.com |
| Name | Affiliation | Role |
|---|---|---|
| Janssen Cilag S.A.S., France Clinical Trial | Janssen Cilag S.A.S. | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Institut Universitaire du Cancer Toulouse Oncopole | Recruiting | Toulouse | 31059 | France |
The data sharing policy of Johnson & Johnson Innovative Medicine is available at innovativemedicine.jnj.com/our-innovation/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
|
| Ibrutinib | Drug | No drug will be administered as a part of this study. Participants received ibrutinib as per their routine clinical practice settings. |
|
| Baseline, Month 4.5, Month 6.5, and Month 12 |
| Change from Month 4.5 in HRQoL by Using FACT-Leu Total Score at Month 6.5 | The FACT-Leu questionnaire consists of 44 questions grouped into 5 dimensions: PWB (7 items), SWB (7 items), EWB (6 items), FWB (7 items) and additional concerns (LEUS; 17 items). Each item is given a weighted score of 0 to 4 and the score of each dimension are obtained by addition of the weighted scores of each item corresponding to the dimension. Total FACT-Leu score is the summation of 5 subscale scores and ranges from 0-176. Higher scores for the scales and subscales indicate better HRQoL. | Month 4.5 and Month 6.5 |
| Change from Month 6.5 in HRQoL by Using FACT-Leu Total Score at Month 12 | The FACT-Leu questionnaire consists of 44 questions grouped into 5 dimensions: PWB (7 items), SWB (7 items), EWB (6 items), FWB (7 items) and additional concerns (LEUS; 17 items). Each item is given a weighted score of 0 to 4 and the score of each dimension are obtained by addition of the weighted scores of each item corresponding to the dimension. Total FACT-Leu score is the summation of 5 subscale scores and ranges from 0-176. Higher scores for the scales and subscales indicate better HRQoL. | Month 6.5 and Month 12 |
| Change from Baseline in HRQoL by Using Trial Outcome Index (TOI) Total Score at Month 4.5, Month 6.5, and Month 12 | The TOI questionnaire consists of 31 questions grouped into 5 dimensions: PWB (7 items), FWB (7 items) and additional concerns (LEUS; 17 items). Each item is given a weighted score of 0 to 4 and the score of each dimension are obtained by addition of the weighted scores of each item corresponding to the dimension. Total TOI score is the summation of 5 subscale scores and ranges from 0-176. Higher scores for the scales and subscales indicate better HRQoL. | Baseline, Month 4.5, Month 6.5, and Month 12 |
| Change from Month 4.5 in HRQoL by Using Trial Outcome Index (TOI) Total Score at Month 6.5 | The TOI questionnaire consists of 31 questions grouped into 5 dimensions: PWB (7 items), FWB (7 items) and additional concerns (LEUS; 17 items). Each item is given a weighted score of 0 to 4 and the score of each dimension are obtained by addition of the weighted scores of each item corresponding to the dimension. Total TOI score is the summation of 5 subscale scores and ranges from 0-176. Higher scores for the scales and subscales indicate better HRQoL. | Month 4.5 and Month 6.5 |
| Change from Month 6.5 in HRQoL by Using Trial Outcome Index (TOI) Total Score at Month 12 | The TOI questionnaire consists of 31 questions grouped into 5 dimensions: PWB (7 items), FWB (7 items) and additional concerns (LEUS; 17 items). Each item is given a weighted score of 0 to 4 and the score of each dimension are obtained by addition of the weighted scores of each item corresponding to the dimension. Total TOI score is the summation of 5 subscale scores and ranges from 0-176. Higher scores for the scales and subscales indicate better HRQoL. | Month 6.5 and Month 12 |
| Change from Baseline in HRQoL by Using FACT-G Scale at Month 6.5 and Month 12 | The FACT-G consists of 27 questions grouped in 4 dimensions: physical well-being (PWB; 7 items), social/family well-being (SWB; 7 items), emotional well-being (EWB; 6 items), and functional well-being (FWB; 7 items). Each item is given a weighted score of 0 to 4 and the score of each dimension are obtained by addition of the weighted scores of each item corresponding to the dimension. Total FACT-G score is the summation of 4 subscale scores and ranges from 0-108. Higher scores for the scales and subscales indicate better HRQoL. | Baseline, Month 6.5, and Month 12 |
| Change from Month 4.5 in HRQoL by Using FACT-G Scale at Month 6.5 | The FACT-G consists of 27 questions grouped in 4 dimensions: physical well-being (PWB; 7 items), social/family well-being (SWB; 7 items), emotional well-being (EWB; 6 items), and functional well-being (FWB; 7 items). Each item is given a weighted score of 0 to 4 and the score of each dimension are obtained by addition of the weighted scores of each item corresponding to the dimension. Total FACT-G score is the summation of 4 subscale scores and ranges from 0-108. Higher scores for the scales and subscales indicate better HRQoL. | Month 4.5 and Month 6.5 |
| Change from Month 6.5 in HRQoL by Using FACT-G Scale at Month 12 | The FACT-G consists of 27 questions grouped in 4 dimensions: physical well-being (PWB; 7 items), social/family well-being (SWB; 7 items), emotional well-being (EWB; 6 items), and functional well-being (FWB; 7 items). Each item is given a weighted score of 0 to 4 and the score of each dimension are obtained by addition of the weighted scores of each item corresponding to the dimension. Total FACT-G score is the summation of 4 subscale scores and ranges from 0-108. Higher scores for the scales and subscales indicate better HRQoL. | Month 6.5 and Month 12 |
| Percentage of Participants Achieving a Greater Than or Equal to (>=) 5-Point Improvement in the FACT-G Total Score at Months 4.5, 6.5, and 12 as Compared to Baseline | The FACT-G consists of 27 questions grouped in 4 dimensions: physical well-being (PWB; 7 items), social/family well-being (SWB; 7 items), emotional well-being (EWB; 6 items), and functional well-being (FWB; 7 items). Each item is given a weighted score of 0 to 4 and the score of each dimension are obtained by addition of the weighted scores of each item corresponding to the dimension. Total FACT-G score is the summation of 4 subscale scores and ranges from 0-108. Higher scores for the scales and subscales indicate better HRQoL. | Baseline, Month 4.5, Month 6.5, and Month 12 |
| Change from Baseline in the Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Total Score at Month 4.5, Month 6.5, and Month 12 | The FACIT-fatigue is a questionnaire that assesses self-reported tiredness, weakness, and difficulty conducting usual activities due to fatigue. The subscale consists of 13-item instrument to measure fatigue. Each of the 13 items has a set of five response categories: Not at all (=0), A little bit (=1), Somewhat (=2), Quite a bit (=3) and Very much (=4). A total FACIT-Fatigue subscale score is calculated as the sum of the 13 item scores (reserved scores [4 - score]) and ranges from 0 to 52, with a higher score indicating less fatigue. Positive changes from baseline indicate improvement of fatigue. Items are reverse scored when appropriate to provide a scale in which higher scores represent better functioning or less fatigue. | Baseline, Month 4.5, Month 6.5, and Month 12 |
| Change From Baseline in Total Sleep Time Using Connected Watch | Change from baseline in total sleep time (in hours) using connected watch will be assessed. | Baseline, Month 4.5, Month 6.5, and Month 12 |
| Change From Baseline in Total Sleep Score Using Connected Watch | Change from baseline in total sleep score (time asleep/time in bed) based on duration, regularity, depth and interruption using connected watch will be assessed. | Baseline, Month 4.5, Month 6.5, and Month 12 |
| Change From Baseline in Sleep Stages Using Connected Watch | Change from baseline in sleep stages (deep/light) using connected watch will be assessed. | Baseline, Month 4.5, Month 6.5, and Month 12 |
| Change From Baseline in Hospital Anxiety and Depression (HAD) Score at Month 4.5, Month 6.5, and Month 12 | The HAD scale is a 14-items measure that assesses anxiety and depressive disorders. The scale includes seven questions related to anxiety (total A) and seven others to the depressive dimension (total D). Each item is rated from 0 to 3. Two scores are derived from the scale, one related to anxiety and the other related to depression (maximum score for each score = 21). Higher scores indicate increased anxiety or depression. | Baseline, Month 4.5, Month 6.5, and Month 12 |
| Change From Baseline in Physical Fitness as Measured by Six-Minute Walk Test (6MWT) at Month 4.5, Month 6.5, and Month 12 | The 6MWT is a submaximal exercise test that entails measurement of distance walked over a span of 6 minutes. It is easy to administer, better tolerated, and more reflective of activities of daily living than the other walk tests. | Baseline, Month 4.5, Month 6.5, and Month 12 |
| Change From Baseline in Physical Activity as Assessed by Number of Steps per Day Using Connected Watch | Change from baseline in physical activity as assessed by number of steps per day using connected watch will be reported. | Baseline, Month 4.5, Month 6.5, and Month 12 |
| Change From Baseline in Physical Activity as Assessed by the Number of Walking Sessions per Week using Connected Watch | Change from baseline in physical activity as assessed by the number of walking sessions per week using connected watch will be reported. | Baseline, Month 4.5, Month 6.5, and Month 12 |
| Change From Baseline in Physical Activity as Assessed by the Time of Walking Sessions per Week Using Connected Watch | Change from baseline in physical activity as assessed by the time of walking sessions per week using connected watch will be reported. | Baseline, Month 4.5, Month 6.5, and Month 12 |
| Change From Baseline in Physical Activity as Assessed by the Distance of Walking Sessions per Week Using Connected Watch | Change from baseline in physical activity as assessed by the distance of walking sessions per week using connected watch will be reported. | Baseline, Month 4.5, Month 6.5, and Month 12 |
| Percentage of Participants with Treatment-related Adverse Events | Percentage of participants with treatment-related adverse events especially musculoskeletal and cardiovascular treatment-related adverse events will be reported. | Up to 30 months |
| Time to Treatment Discontinuation (TTD) | TTD is defined as the time between the first day of ibrutinib treatment and the day that ibrutinib is definitely stopped for whatever reason or death. | Months 6 and 12 |
| Reasons for Treatment Discontinuation | Number of participants in each reason for treatment discontinuation will be reported. Reasons for treatment discontinuation are defined as: adverse events, lack of efficacy, patient's convenience, physician's decision, progression, death or other. | Up to Month 12 |
| Percentage of Participants Who Still Wear the Connected Watch | Percentage of participants who still wear the connected watch (adherence) will be assessed. | Months 1, 3, 4.5, 6.5, and 12 |
| Percentage of Participants Retained by the Connected Watch (Start Wearing the Watch) | Percentage of participants retained by the connected watch (start wearing the watch) will be assessed. | Months 1, 3, 4.5, 6.5, and 12 |
| Percentage of Participants Agreed to Participate in the Study Among Eligible participants with Chronic Lymphocytic Leukemia (CLL) Initiation Ibrutinib Treatment | Percentage of participants agreed to participate in the study among eligible participants with CLL initiation ibrutinib treatment will be reported. | During the first 6 months (Feasibility period) |
| For Group 1: Percentage of Participants Who Still Follow the Individual Physical Activity Intervention (IPAI) Among Those Who Have Started IPAI | Percentage of participants who still follow the IPAI among those who have started IPAI (Adherence) in group 1 will be assessed. | Months 1, 3, 4.5, and 6.5 |
| For Group 1: Percentage of Participants Who Follow the Adapted Physical Activity (APA) Sessions, the Walking Objectives and the APA Appointment as Scheduled With the APA Among Those Who Have Started IPAI | Percentage of participants who follow the adapted physical activity sessions, the walking objectives and the APA appointment as scheduled with the APA among those who have started IPAI (Compliance) in group 1 will be assessed. | Months 1, 3, 4.5, and 4.6 |
| For Group 1: Percentage of Participants Retained by the IPAI (First APA Videoconference Attended) Among Participants Enrolled in the Study | Percentage of participants retained by the IPAI (first APA videoconference attended) among participants enrolled in the study will be assessed. | Months 1 and 3 |
| For Group 1: Percentage of Participants who Completed the Supervised Period Among Participants Enrolled in the Study | Percentage of participants who completed the supervised period among participants enrolled in the study will be assessed. | Month 4.5 |
| For Group 1: Percentage of Participants who Completed the Unsupervised Period Among Participants Enrolled in the Study | Percentage of participants who completed the unsupervised period among participants enrolled in the study will be assessed. | Month 6.5 |
| For Group 1: Participant Satisfaction With the IPAI Measured With the Satisfaction Likert Scale | Participant's' satisfaction will be assessed by Likert scales at Months 4.5 and 6.5 regarding coaching, proposed sessions, program content, program duration, impact on APA practice, overall satisfaction, willingness to continue and recommendation to others. Likert scales will assess participant's' satisfaction at Month 12 regarding impact on APA practice, overall satisfaction, willingness to continue and recommendation to others. Only one question is quantitative with score range from 0 (not at all satisfied) to 10 (totally satisfied) for global satisfaction. Participants are considered satisfied when score is greater than or equal to (>=) 6 and highly-satisfied when score is >=8. All other questions are qualitative and have 5-level Likert scales including: very satisfied, rather satisfied, neither satisfied nor dissatisfied, not really satisfied, not at all satisfied. | Months 4.5, 6.5, and 12 |
| ID | Term |
|---|---|
| D015451 | Leukemia, Lymphocytic, Chronic, B-Cell |
| ID | Term |
|---|---|
| D015448 | Leukemia, B-Cell |
| D007945 | Leukemia, Lymphoid |
| D007938 | Leukemia |
| D009370 | Neoplasms by Histologic Type |
| D009369 | Neoplasms |
| D006402 | Hematologic Diseases |
| D006425 | Hemic and Lymphatic Diseases |
| D008232 | Lymphoproliferative Disorders |
| D008206 | Lymphatic Diseases |
| D007160 | Immunoproliferative Disorders |
| D007154 | Immune System Diseases |
| D002908 | Chronic Disease |
| D020969 | Disease Attributes |
| D010335 | Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |
Not provided
Not provided
| ID | Term |
|---|---|
| C551803 | ibrutinib |
Not provided
Not provided
Not provided